Insulet (PODD) Revenue Growth (1y) (2011 - 2026)
Insulet (PODD) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 7.78% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 2.63% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 9.86% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 11.58% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 16.70% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 15.05% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 7.41% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 6.08% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 33.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.87% |
| Dec 31, 2025 | 31.18% |
| Sep 30, 2025 | 29.86% |
| Jun 30, 2025 | 32.88% |
| Mar 31, 2025 | 28.82% |
| Dec 31, 2024 | 17.20% |
| Sep 30, 2024 | 25.70% |
| Jun 30, 2024 | 23.20% |
| Mar 31, 2024 | 23.35% |
| Dec 31, 2023 | 37.90% |
| Sep 30, 2023 | 26.97% |
| Jun 30, 2023 | 32.43% |
| Mar 31, 2023 | 21.23% |
| Dec 31, 2022 | 20.15% |
| Sep 30, 2022 | 30.18% |
| Jun 30, 2022 | 15.20% |
| Mar 31, 2022 | 17.08% |
| Dec 31, 2021 | 25.03% |
| Sep 30, 2021 | 11.88% |
| Jun 30, 2021 | 14.85% |